SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: rexnine who wrote (115)2/21/2000 8:22:00 PM
From: SunAge  Respond to of 1833
 
I'd imagine the U.S. Patent Office would definitely scrutinize the patent. Both companies will be affected, however, more so on Sibia than Cadus.

It would be poetic justice, if before the appeal gets heard, the patent is deemed invalid. I wonder if there have been any updates or correspondences sent by the U.S. Patent Office to both companies for the past 17 months. I'm leaning towards some form of updates and requests for additional documentations.

I'm speculating here that if Osip is confident enough to license technology from Cadus, could it be that other companies will follow soon? Also, could this new optimism be in any way related with the possible outcome of the patent dispute with Sibia?



To: rexnine who wrote (115)2/22/2000 7:14:00 AM
From: SunAge  Respond to of 1833
 
A quote from a recent article in the Economist re software patents:

By law, no invention can be patented that has already been patented by someone else or has been published prior to the time the patent is filed; in the language of the legal system, such patents and publications are known as "prior art."


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News